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Abstract
Background: The NADPH redox cycle plays a key role in antioxidant protection of human erythrocytes. It consists of two
enzymes: glucose-6-phosphate dehydrogenase (G6PD) and glutathione reductase. Over 160 G6PD variants have been
characterized and associated with several distinct clinical manifestations. However, the mechanistic link between the
genotype and the phenotype remains poorly understood.
Methodology/Principal Findings: We address this issue through a novel framework (design space) that integrates
information at the genetic, biochemical and clinical levels. Our analysis predicts three qualitatively-distinct phenotypic
regions that can be ranked according to fitness. When G6PD variants are analyzed in design space, a correlation is revealed
between the phenotypic region and the clinical manifestation: the best region with normal physiology, the second best
region with a pathology, and the worst region with a potential lethality. We also show that Plasmodium falciparum,b y
induction of its own G6PD gene in G6PD-deficient erythrocytes, moves the operation of the cycle to a region of the design
space that yields robust performance.
Conclusions/Significance: In conclusion, the design space for the NADPH redox cycle, which includes relationships among
genotype, phenotype and environment, illuminates the function, design and fitness of the cycle, and its phenotypic regions
correlate with the organism’s clinical status.
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Introduction
The NADPH redox cycle plays a key role in the oxidative stress
response of human erythrocytes. It consists of two enzymes:
glucose-6-phosphate dehydrogenase (G6PD, EC 1.1.1.49) and
glutathione reductase (GSR, EC 1.8.1.7). Although variants of
G6PD have been intensively studied and are associated with
several distinct clinical manifestations, the relationship between
the genotype and the phenotype is still poorly understood. To
address this issue, we have constructed a ‘‘system design space’’
which facilitates the quantitative comparison of wild-type and
variants for the redox cycle. Our results identify three different
phenotypes that correlate with clinical manifestations.
G6PD catalyses the first step of the hexose-monophosphate
shunt (Figure 1A), which provides pentoses for nucleic acid
synthesis and regenerates NADPH. In erythrocytes, NADPH is
required for various processes, but most of it is oxidized by GSR
[1]. The latter process regenerates reduced glutathione (GSH) that
is oxidized in the repair of oxidative damage. In mice, and
presumably in other organisms, G6PD is dispensable for pentose
synthesis but essential for defense against oxidative stress [2]. High
levels of G6PD exist for this function, but under pronounced
oxidative stress hexokinase (EC 2.7.1.1) becomes rate-limiting for
the NADPH supply [3].
Previous quantitative analysis of the NADPH redox cycle [4,5]
indicates that normal G6PD activity is sufficient but not
superfluous to avoid NADPH depletion and ensure timely
adaptation of the NADPH supply during pulses of oxidative load
such as those that occur during adherence of erythrocytes to
phagocytes. The quantitative analysis of this system has been
facilitated by two recent developments: a method for constructing
the ‘‘system design space’’ [6] and a related method for calculating
‘‘global tolerances’’ [7] to large variations in the values of system
parameters and environmental inputs.
In this paper we utilize the design space as a framework to
compare the quantitative phenotypes of wild-type and mutant
variants of the NADPH redox cycle. In particular, 160 G6PD
variants have been characterized [8], and there are several distinct
phenotypes associated with G6PD deficiency [9]. This system
presents a unique opportunity to relate genotype to phenotype by
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redox cycle. Our analysis of this system and its mutants requires
additional background regarding its biochemistry, genetics and
clinical manifestations.
G6PD in its active form is made up of two or four identical
subunits, each with a molecular mass of 59 kDa. The gene for
G6PD is on the X-chromosome, and the deficiency is inherited in
a sex-linked fashion. Hemizygous males and homozygous females
with low-activity mutant forms of the enzyme carry only G6PD-
deficient erythrocytes. However, female heterozygotes carry both
normal and deficient erythrocytes. The latter outcome is due to
the fact that each cell inactivates one of its X-chromosomes,
chosen at random. The most common G6PD form worldwide is
the B form. However, in Africa up to 40% of the population carry
the non-deficient A form of G6PD [10]. The most common
G6PD-deficient variant in Africa is the A- allele with a frequency
between 0 and 25% [11].
Over 400 million people in the world suffer from G6PD
deficiency; which makes it the most common known enzymo-
pathy. The highest prevalence rates are found in tropical and
subtropical regions of the world and in some areas of the
Mediterranean. It would be difficult to understand the existence of
such a widespread enzymatic deficiency without a counterbalanc-
ing biological advantage. The observation that the G6PD A-
mutation has fitness costs such as making individuals more prone
to develop hemolytic anemias [12] makes this issue even more
intriguing. In 1960, Allison [13] and Motulsky [14] first suggested
that individuals deficient in G6PD might be at a selective
advantage in malaria endemic areas. However, numerous clinical
studies have yielded conflicting results over the alleged protective
role of G6PD deficiency against malaria. In particular, clinical
studies of severe malaria have shown a protective role for G6PD
deficiency in hemizygous males [15,16] while, in heterozygous
females, there is either a protective effect [16] or no effect [15].
The studies relating to uncomplicated malaria have shown more
conflicting results with heterozygous females protected [16,17,
18,19], at increased risk [20], or unaffected by G6PD deficiency
[21]. In a recent paper, Johnson M.K. et al. [22] compared the
association between uncomplicated malaria incidence and G6PD
deficiency using the two different methods currently available:
G6PD enzyme activity and G6PD genotype assessment. They
found a 52% reduced risk of uncomplicated malaria in G6PD-
deficient females when the deficiency was assessed using enzyme
activity. When the assessment method was based on the genotype,
the protective association was no longer significant, which is likely
due to the large dispersion in enzymatic activity caused by random
X-chromosome inactivation [22]. For G6PD deficient males, there
was no association with the incidence of uncomplicated malaria
regardless of assessment method. Their work suggests that the
conflict between prior association studies might be related to the
method of G6PD assessment.
G6PD variants have been described on the basis of their
biochemical properties and grouped into five classes according to
the level of enzyme activity and clinical manifestations. In 1967, a
committee of the World Health Organization [23] recommended
standard techniques for the biochemical characterization of G6PD
variants. Class I includes severely deficient variants that suffer
from chronic non-spherocytic haemolytic anemia. Class II variants
have less than 10% enzyme activity but do not suffer from chronic
non-spherocytic haemolytic anemia. Class III variants are
moderately deficient (10–60% activity). Class IV has normal
enzyme activity (60–150%) and in Class V the enzyme activity is
higher than normal (.150% activity) [24]. Of the 400 million
people worldwide that exhibit G6PD deficiency, there are, for
instance, 4 million African Americans (1 in 10) [25] in a country
where malaria has been eradicated since 1951 [26]. Thus, the
implications of G6PD deficiencies unrelated to malaria represent a
significant medical problem [27].
In terms of clinical manifestations, G6PD deficiency can be
divided into 3 groups. The first group (Class IV and V) consists of
variants that do not have any clinical disorder. The second group
Figure 1. Oxidative part of the hexose monophosphate shunt
and core reactions of the NADPH redox cycle. Schematic
representations of (A) the shunt and relevant sources of oxidative load
and (B) the NADPH redox cycle. Abbreviations: ADP – adenosine 5-
diphosphate, ATP – adenosine 5-triphosphate, Glc – glucose, G6P –
glucose 6-phosphate, G6PD – glucose 6-phosphate dehydrogenase,
GO6PD – gluconate 6-phosphate dehydrogenase, GPx – glutathione
peroxidase, GSH – reduced glutathione, GSR – glutathione reductase,
GSSG – oxidized glutathione, HK – hexokinase, NADP
+ – oxidized
nicotinamide adenine dinucleotide phosphate, NADPH – reduced
nicotinamide adenine dinucleotide phosphate.
doi:10.1371/journal.pone.0013031.g001
NADPH Redox Cycle Phenotypes
PLoS ONE | www.plosone.org 2 September 2010 | Volume 5 | Issue 9 | e13031(Class II and III) shows a hemolytic reaction that is triggered by
certain drugs, by infection or by the ingestion of certain foods. The
mechanism of hemolysis is not known, but it has been proposed
that it results from the inability of G6PD-deficient erythrocytes to
cope with the oxidative damage produced by the agents
mentioned above [28]. The third group (Class I) may be classified
as having chronic non-spherocytic hemolytic anemia, which is
exacerbated by oxidative stress.
In this paper, we assembled existing data into an integrated
model of the NADPH redox cycle that allowed us to address the
following questions: given the variability in G6PD, how do
mutations affect the quantitative performance of the cycle? Is there
a correlation between clinical manifestations and poor perfor-
mance of the NADPH redox cycle? Finally, how does infection of
erythrocytes by Plasmodium falciparum affect the redox cycle. We
base our analysis of these questions on the model shown in
Figure 1B.
Methods
Model Formulation
Under physiological conditions, the steps catalyzed by G6PD
and GSR are essentially irreversible [29]. The kinetic parameters
of each enzyme and the nominal concentrations of their reactants
have been well characterized (Table 1).
G6PD Kinetics. The rate expression for G6PD follows a
compulsory order mechanism in which NADPz binds first to the
enzyme:
VG6PD~
VMax,G6PD
1z
KM,G6P
G6P
z
K
App
M,NADPz
NADPz z
KM,G6P
G6P
KE,NADPz
NADPz
ð1Þ
here,
K
App
M,NADPz~KM,NADPz 1z
NADPH
KI,NADPH
z
2,3{DPG
KI,2,3{DPG

is the apparent Michaelis-Menten constant for NADP
+ after taking
into account the competitive inhibition by NADPH and 2,
3-diphosphoglycerate (2,3-DPG). In Table 1, we present the
experimental values of kinetic parameters for G6PD encoded by
the B-form of the gene.
GSR Kinetics. At concentrations of oxidized glutathione
(GSSG) typical of low to moderate oxidative loads, GSR follows a
ping-pong mechanism with rate expression:
VGSR~
VMax,GSR
1z
KM,GSSG
GSSG
z
KM,NADPH
NADPH
ð2Þ
The kinetic parameters of GSR are given in Table 1.
Piecewise Power-Law Representation
Using the method outlined in [7], we combined the fundamen-
tal enzyme kinetic rate laws and the conservation of the NADP
moiety into a system of ordinary differential equations represent-
ing mass balance, which can then be solved to determine the
steady-state of integrated system. With this approach, we are able
to formulate the piecewise power-law representation of G6PD
[Eq(3)] and GSR [Eq (4)] kinetics in normalized form:
Log vG6PD ðÞ ~Log
u=ku
u=kuz1

~
Log u=ku ðÞ ,f o r uvku
Log 1 ðÞ ,f o r uwku

ð3Þ
and
Log vGSR ðÞ ~Log r
c=kc
c=kcz1

~
Log rc=kc ðÞ ,f o r cvkc
Log r ðÞ ,f o r cwkc

ð4Þ
where:
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;u~
NADPz
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V
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Table 1. Values of the kinetic parameters and concentration
variables for the enzymes of the NADPH redox cycle.
Enzyme Parameter Value Ref.
G6PD (B-form) VMax,G6PD *130 mMs
21 [40]
KM,G6P 38 mM [41]
KM,NADPz 6.5 mM [41]
KE,NADPz 7.9 mM [41]
KI,NADPH 7.1 mM [41]
KI,2,3{DPG 2.3 mM [3]
[G6P] 39 mM [42]
[2,3-DPG] 3.1 mM [29]
GSR VMax,GSR 49 mMs
21 [40]
KM,NADPH 8.5 mM [43]
KM,GSSG 65 mM [43]
[GSSG] 0.16 mM [4]
NADPtotal ½  ~ NADPH ½  z NADPz ½  2.7 mM [4]
*The maximum velocity for synthesizing NADPH is twice the maximum velocity
of G6PD (to take into account the GO6PD activity). For further details see [4].
doi:10.1371/journal.pone.0013031.t001
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NADP
+ scaled by NADPtotal and it takes into account product-
inhibition and the inhibition by 2,3-DPG. Conversely, kc
represents the apparent Michaelis constant for NADPH scaled
by NADPtotal. The parameter r represents the ratio between the
apparent maximal velocity of GSR and the apparent maximal
velocity of G6PD.
Based on this representation, we recognize that the NADPH
redox cycle in human erythrocytes can operate under three
different meaningful steady-state regimes (Table 2) and one
unrealistic case (with uwku, cwkc, r~1) (see Text S1). Each
systemic regime will only apply to a particular region of the design
space (see Figure 2), which is obtained by using the methods
previously described [6,7].
Determination of System Behavior within each Regime
The system representation within each regime is a simple but
nonlinear S-system equation for which determination of local
behavior, after appropriate transformation, reduces to conven-
tional linear analysis [30]. Thus, the local behavior is completely
determined and readily characterized by the evaluation of the
following quantitative indices.
Logarithmic gains. The change of concentration (e.g.,
NADPH) or flux in response to a change in value for an
independent variable (e.g., GSSG) is defined by a relative
derivative of the explicit steady-state solution. For example,
L(NADPH,GSSG)~
LLogNADPH
LLogGSSG
~
LNADPH
LGSSG
GSSG
NADPH
ð5Þ
Parameter sensitivities. The change of concentration or
flux in response to a change in value for one of the parameters that
define the structure of the system (e.g., Michaelis constants) is also
determined by a relative derivative of the explicit steady-state
solution. For example,
S(NADPH,KM,G6P)~
LLogNADPH
LLogKM,G6P
~
LNADPH
LKM,G6P
KM,G6P
NADPH
ð6Þ
Response time. The eigenvalue, which in the present case is
an inverse measure of the system’s response time, is determined by
a first-order Taylor series approximation in logarithmic space of
the differential equation about the steady-state that applies for
each systemic regime.
Criteria for Functional Effectiveness
The performance of the NADPH redox cycle can be evaluated
in each systemic regime according to the following quantitative
criteria:
Figure 2. Design space of the NADPH redox cycle. Three distinct operating regimes labeled a, b and c are depicted for the cycle in Figure 1B
(see Table 2). In Panel A, the apparent Michaelis constant for NADPH is smaller than the total concentration of NADP which implies kcv1 (see Eqns.
3 and 4). In Panel B, the relationship is reversed and, therefore, kcw1. The x-axis, rho, represents the ratio between the apparent maximal velocity of
GSR and the apparent maximal velocity of G6PD. The y-axis, ku represents a scaled apparent Michaelis constant for NADP
+ (see Eqns. 3 and 4).
doi:10.1371/journal.pone.0013031.g002
Table 2. Steady-state values for fluxes and concentrations of the NADPH redox cycle in each regime.
Regime Log vG6PD ðÞ Log vGSR ðÞ Steady-State Equation*
a Log u
ku

Log r ðÞ c~1{r ku
b Log 1 ðÞ Log r c
kc

c~
kc
r
c Log u
ku

Log r c
kc

c~
kc
kczrku
*Note that u~1{c and that ku involves the dependent variable c. The normalized symbols in this table can be expressed in terms of the original parameters by means
of equations 3 and 4. For a complete description of the steady-state solutions see Text S1.
doi:10.1371/journal.pone.0013031.t002
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Criterion 1: fluctuations in the values for the kinetic
parameters of G6PD and GSR and of the
total amount of NADP present in the
erythrocyte;
Criterion 2: changes in the concentration of GSSG;
Criterion 3: changes in the concentration of G6P.
The supply of NADPH (VG6PD) should
Criterion 4: be responsive to changes in the concen-
tration of GSSG.
The sensitivity of the supply of NADPH to changes in the
concentration of GSSG should
Criterion 5: be well buffered against fluctuations in the
values for the kinetic parameters of G6PD
a n dG S Ra n do ft h ei n d e p e n d e n tv a r i a b l e s ;
The response time should
Criterion 6: be fast, and
Criterion 7: well buffered against fluctuation in the values
for the kinetic parameters and independent
variables.
Statistical Tests
All of thestatistical tests described below, except one, wereperformed
with algorithms in Mathematica available through reference [31].
Parametric. Single-factor Analysis of Variance (ANOVA) is
a method used to decide whether differences exist among several
population means. It requires all populations to be normally
distributed (D’Agostino-Pearson Test for nonnormality) and
exhibit the same variance (Bartlett’s test for equality of variance).
We tried to transform the data so as to satisfy these assumptions
whenever either was violated. Whenever the ANOVA rejected
equality of all means we investigated each pairwise comparison of
population means for significant differences using Tukey’s honestly
significant difference (HSD) test.
Non-Parametric. Whenever the transformation procedure
failed to satisfy the ANOVA assumptions, we used a
nonparametric method: the Kruskal-Wallis One Way Analysis of
Variance. If it was significant, it indicated that at least one of the
populations was different from at least one of the others. We used
a procedure called ‘‘kruskalmc’’ written for R (included in package
pgirmess [32]) to perform a multiple comparison test between
populations after the Kruskal-Wallis test (the nonparametric
equivalent of a Tukey’s honestly significant difference test). This
test helped to determine which populations were different in
pairwise comparisons adjusted appropriately [33].
Results
The local performance within the three systemic regimes is
determined by the above methods and evaluated according to the
previously defined criteria. Our aim is to ascertain which of the
systemic regimes is better suited for effective performance of the
NADPH redox cycle.
Analysis of Local Performance
In Table 3,w es u m m a r i z et h er e s u l t sf r o mt h ea n a l y s i so fl o c a l
performance in Systemic Regimes a, b and c (for further details see
Text S1). These results show that local performance in Systemic
Regime afulfills all the criteria defined above. In contrast, performance
in Systemic Regimes b and c cannot fulfill criteria 4 and 5 because
there is no response to changes in the concentration of GSSG.
Moreover, the local robustness (criterion 1) of systems represented in
Systemic Region b is significantly worse than that of systems in either
Systemic Region a or c (see Text S1).
Additionally, although Systemic Regimes b and c can exhibit a
fast response time (Criterion 6), it will not be with respect to
changes in GSSG. Therefore, the importance of this responsive-
ness is questionable.
In summary, we predict that, under basal conditions, the NADPH
redox cycle should operate in Systemic Regime a, which has the best
overall local performance. Moreover, natural selection should
maintain the operating point far from the boundary to region c,
which has less desirable overall local performance, and especially from
the boundary to region b, which has the worst performance.
Analysis of Global Tolerance
The boundaries of Systemic Regime a are obtained by inserting the
linear solution into the corresponding linear breakpoint conditions:
uvku and cwkc ð7Þ
The result is the following set of boundaries
1{kcw0 and rv1 and kuv
1{kc
r
ð8Þ
Equations (8) can be represented in terms of the fundamental
parameters and variables by substituting the definitions given previously
1{
KM,NADPHGSSG
NADPtotal KM,GSSGzGSSG ðÞ
w0 and
VMax,GSRGSSG
KM,GSSGzGSSG
v
VMax,G6PDG6P
KM,G6PzG6P
and
KE,NADPzz
G6P
KM,G6P
KM,NADPz 1z
NADPHsteady{state
KI,NADPH
z
2,3{DPG
KI,2,3{DPG

NADPtotal 1z
G6P
KM,G6P
 v
1{
KM,NADPHGSSG
NADPtotal KM,GSSGzGSSG ðÞ
VMax,GSRGSSG KM,G6PzG6P ðÞ
VMax,G6PDG6PK M,GSSGzGSSG ðÞ
ð9Þ
Table 3. Evaluation of the local performance in Systemic
Regimes a, b and c.
Capable of being fulfilled by regime:
Criterion* ab c
1 ++ +
2 ++ +
3 ++ +
4 + 22
5 + 22
6 ++ +
7 ++ +
*The criteria were listed under the sub-section ‘‘Criteria for Functional Effectiveness’’ of
the Methods. The symbol ‘‘+’’ indicates been able to fulfill the criterion by a par-
ticular regime while the symbol ‘‘2’’ indicates the failure to satisfy a given criterion.
doi:10.1371/journal.pone.0013031.t003
ð9Þ
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NADPHsteady{state~
NADPtotal{
r
KM,G6PzG6P
KM,G6PKE,NADPzzKM,NADPzG6P 1z
2,3{DPG
KI,2,3{DPG
 
1z
rG6PK M,NADPz
KI,2,3{DPG KM,G6PzG6P ðÞ
Systems represented within these boundaries exhibit the best local
performance and thus these boundaries provide the basis for the
analysis of global tolerance.
Analysis of the normal G6PD (B form)
The most common variant of G6PD worldwide is the B form.
Given the detailed description of this variant form of G6PD
(Table 1) and of GSR, we are able to locate the operating point
for G6PD B (Figure 3, black circle) in the design space and show
the normalized steady-state concentration of NADPH in the z-
direction with a heat map.
The local behavior of the NADPH redox cycle can be evaluated
according to the seven criteria (Table 4, upper panel)d e s c r i b e d
earlier and, given the boundaries surrounding Systemic Region a
(Eq. 9), we are able to determine the numerical value of global
tolerance for each of the kinetic parameters and independent
concentration variables (Table 4, lower panel). We will use the
expression ‘‘½TD,TI ’’ to describe the global tolerances, where
TD~tolerance to a fold decrease and TI~tolerance to a fold
increase (since boundaries can be crossed either by decreasing or
increasing a parameter).
As can be seen from the results in Table 4 (upper panel),
natural selection results in a design that has nearly optimal local
performance when we consider the normal variant of G6PD (B-
form). In a similar trend, the global tolerances (Table 4, lower
panel) range from the smallest of 63 fold to the largest of 1.4610
5.
The smallest value is associated with the concentrations of
NADPtotal and GSSG, whereas the largest is associated with the
product inhibition constant of G6PD.
Analysis of the G6PD variants
The biochemical properties of more than 400 putative variants
have been tabulated in a review [9]. Detailed comparisons of the
tabulated values and the values in the corresponding original
literature show a number of irregularities. Thus, we have
systematically re-evaluated the original literature and produced a
revised set of tables for the various classes that highlights the
discrepancies (see Text S2).
After eliminating the anomalous cases, we focused on the
remaining G6PD variants for which there are documented
experimental values for: KI,NADPH, KM,G6P, KM,NADPz and
VMax,G6PD. Furthermore, all variants under analysis were
characterized according to the standard techniques that the World
Health Organization [23] recommended in 1967. We excluded
variants (see [9] and Text S2) for which one or more of the kinetic
parameters is unknown, or whose kinetics were characterized
according to non-standard techniques.
In order to analyze the local performance and global tolerance
of the NADPH redox cycle in which variants of G6PD participate,
we assumed that KI,2,3{DPG, KE,NADPz, the kinetic parameters of
GSR and all the independent variables retain their normal value.
Location of the G6PD Variants in Design Space. In
Figure 3, we display the location of the operating point of the
G6PD variants in the Design Space for the NADPH redox cycle.
Class III (blue circle) and Class IV (orange circle) variants have
their operating points located well within Systemic Region a.
Moreover, we can visually ascertain that Class IV variants are
further away from Systemic Region c than Class III variants.
However, Class II (green circle) and Class I (red circle) variants
have operating points that span Systemic Regions a and c. This
result proves important because we know that the Class I and II
variants have clinical manifestations. Therefore, there is a
correlation between a Class being near to or present in Systemic
Region c and the existence of clinical problems. Furthermore,
several considerations suggest that if the operating point of a
variant of G6PD were to be located within Systemic Region b, this
might be lethal to the host. First, Systemic Region b has the worst
local performance. Since being present in Systemic Region c is
already associated with life-threatening medical conditions, we can
only expected that being present in an even worse phenotypic
region could be lethal. Second, no known variant of G6PD leads to
an operating point located within Systemic Region b. Moreover,
the observation that all known variants of G6PD are located in the
design space (kuw1) such that an increase in oxidative stress would
never move their operating points into Systemic Region b suggests
a selective pressure to prevent even temporary excursions into this
region.
Local Performance of G6PD Variants. The local behavior
of the NADPH redox cycle can be evaluated according to the
seven criteria described in the METHODS section and our aim is
to distinguish among the several classes of G6PD variants
(Table 5). Note that we are only considering the G6PD variants
that lead to systems whose operating points lie within Systemic
Region a. Moreover, in this Regime the fulfillment of Criteria 4
and 5 only depends on the concentration of GSSG and on the
Figure 3. Design space of the NADPH redox cycle and location
of G6PD variants. The shading — (white) High to (black) Low —
indicates the logarithm of the normalized steady-state concentration of
NADPH, Log NADPH=NADPtotal ½  . The Log-Log coordinates provide a
more convenient representation of the design space that was shown
with Cartesian coordinates in Figure 2A. The three Systemic Regions
are denoted a (physiological phenotype), b (potentially lethal
phenotype), and c (pathological phenotype associated with anemia).
Symbols: black - normal operating point (G6PD-B form); orange - Class
IV variants of G6PD; blue - Class III variants of G6PD; green - Class II
variants of G6PD; red - Class I variants of G6PD. Further details are
described in the legend of Figure 2.
doi:10.1371/journal.pone.0013031.g003
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which are fixed in our analysis. Thus, our comparisons will be
limited to criteria 1, 2, 3, 6 and 7.
From the results in Table 5, we conclude that the worst local
performance is given by systems for which G6PD variants are in
Class I or II. In detail, according to criteria 1, 2, 3 and 6, the local
performance of systems in Class I or II is statistically worse than
those in either Class III or IV. Furthermore, there is no criterion
that allows us to distinguish between Class I and Class II, whereas
the local performance of a cycle with a Class IV variant is
statistically better than a cycle with a Class III variant according to
criteria 2, 3 and 6.
Global Tolerance of G6PD Variants. Once again, we are
only considering the G6PD variants that lead to systems operating
within Systemic Region a. Therefore, we will determine how
much a given kinetic parameter or independent concentration
variable has to change in order to place the NADPH redox cycle
in a different Systemic Region (Table 6).
From the analysis of Table 6, we find that the worst global
tolerances are associated with systems of Class I or II. According to
all the kinetic parameters and independent variables except
KI,NADPH, the global tolerances of Class I or II cycles are
statistically worse than those of either Class III or IV. In addition,
we see that there is no global tolerance that allows us to distinguish
between Class I and Class II. Furthermore, the analysis of global
tolerance, except for KI,NADPH and KM,NADPH, allows us to
differentiate between Class III and Class IV and conclude that
Class IV has better global tolerances than Class III.
Distinguishing Class I from Class II Variants. Our
analysis has shown that there is no local performance criterion
or global tolerance that distinguishes a NADPH redox cycle with a
Class I variant from one with a Class II variant of G6PD.
However, the clinical manifestations are quite different. How
might these differences be reconciled? One possibility is differences
in kinetic properties of Class I and Class II variants of G6PD. In
Table 7, we display the medians of the kinetic properties of the
G6PD variants, when grouped into their respective classes. These
results show that it is possible to make this distinction on the basis
of KI,NADPH: the median of Class I is 7.6 mM while the median of
Class II is 30.5 mM. However, this statistical difference in kinetic
properties does not lead to a statistically significant difference in
local performance or global tolerance (Tables 5 and 6).
Therefore, the difference in kinetic properties is unable to
explain the different clinical manifestations.
Within the context of our model, there are several ways that
these differences can be reconciled. A plausible example would be
Class I variants having a higher value of KE,NADPz. For instance, if
the KE,NADPz were 790 mM in Class I variants rather than the
normal value of 7.9 mM, then the design space of the NADPH
redox cycle would resemble Figure 4, and all Class I variants
would operate in the poor region, Systemic Region c, whereas
most Class II variants would operate in the good region, Systemic
Region a.
Infection by Plasmodium falciparum
It has been shown that P. falciparum can adapt to growth in
G6PD-deficient erythrocytes by producing its own G6PD enzyme
[34].
In one particular study [35], researchers purified G6PD from
infected and uninfected erythrocytes. They found that infected
Table 4. Evaluation of Local Performance and Global Tolerance for the NADPH redox cycle in human erythrocytes with the B-form
(normal) of G6PD.
Local Performance
Criterion1 Preference| Quantitative value{ Optimum value{
1 Y 1.05 1
2 Y 0.01 0
3 Y 0.00 0
4 X 1.00 1
5 Y 0.00 0
6 Y 0.20 0
7 Y 3.49 2
Global Tolerance
Variable or Parameter Tolerance Value* Variable or Parameter Tolerance value
KI,NADPH [1.4610
5 KM,NADPH 126]
G6P [363 VMax,G6PD [122
KM,G6P 363] VMax,GSR 122]
KE,NADPz 363] KM,GSSG [72
2,3{DPG 319] GSSG 72]
KI,2,3{DPG [319 NADPtotal [63
KM,NADPz 183]
1The criteria were listed under the sub-section ‘‘Criteria for Functional Effectiveness’’ of the Methods Section;
|To improve performance, one must have either a high (X) or a low (Y) value for the associated criterion;
{The quantitative value was determined by using the data from Table 1 and the analytical expressions listed in Table S1, S2 of the Text S1;
{The optimum value was determined analytically except for criterion 7 which had to be determined numerically;
*[T represents tolerance to a fold decrease and T] represents tolerance to a fold increase.
doi:10.1371/journal.pone.0013031.t004
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falciparum produces, responsible for 90% of the overall activity, and
the host’s G6PD, responsible for 10%.
In Table 8, we list the experimental values for the kinetic
properties of the host G6PD and the P. falciparum G6PD. By
assuming normal values for the unknown independent variables
and parameters, we are able to plot (Figure 5) the location of the
operating point for the NADPH redox cycle in erythrocytes that
are infected (black rectangle) or uninfected (black diamond) with P.
falciparum.
As can be seen in Figure 5, the uninfected erythrocytes endure
a NADPH redox cycle with poor performance due to the G6PD
deficiency (the operating point is located within Systemic Region
c). However, once P. falciparum infects an erythrocyte and
synthesizes its own G6PD, the operating point of the NADPH
redox cycle will move into the region of best performance
(Systemic Region a). Furthermore, we are able to assess the local
performance and global tolerance of the NADPH redox cycle in
human erythrocytes infected with P. falciparum (Table 9). The
local performance is comparable to the performance of erythro-
cytes in which G6PD is of the B-form (Table 4). The major
difference is in temporal responsiveness. Infected erythrocytes are
more sluggish in responding to changes in GSSG. In terms of
global tolerances, we observe that all tolerances for the infected
erythrocyte are lower. This observation is correlated with the fact
that the normal operating point of the NADPH redox cycle
(G6PD B-form – black circle in Figure 5) is located further away
from the boundary to Systemic Region c than the operating point
of the infected erythrocytes (black rectangle). It is known that P.
falciparum-infected erythrocytes are under a larger oxidative stress
[36] and this effect may move its operating point in the design
space further to the right (black rectangle).
We have to consider these results from the viewpoint of the P.
falciparum. Upon infection of a G6PD-deficient erythrocyte, P.
falciparum induces its own G6PD [34]. According to our analysis,
this induction tends to correct the state of the redox cycle and P.
falciparum can rely on a functional NADPH moiety supply unit.
This scenario raises the question: is there a reason for P. falciparum
to need a reliable NADPH moiety supply unit? P. falciparum digests
the erythrocyte’s hemoglobin and, as a consequence, produces
O{
2 , H2O2 and OH radicals leading to a larger oxidative stress
which the otherwise deficient cycle could not cope [36].
Discussion
The piecewise power-law representation of the rate laws for
G6PD and GSR allowed us to define the design space for the
NADPH redox cycle. This design space has three phenotypic
regions, each defined by a single type of stable steady state.
However, the redox cycle only works properly in Systemic Region
a.
In comparing the local performance and global tolerance of the
several possible cycles, it becomes apparent that an individual who
has inherited the normal form of G6PD (B-form) displays one of
the best possible NADPH redox cycles. One may argue that these
functional advantages may explain the high prevalence of this
form worldwide. In broader terms, we have demonstrated that
there are statistically significant differences in local performance
and global tolerance between cycles with a Class IV variant vs. a
Class III/II/I variant. Individuals with a Class III variant of
G6PD will experience a more sluggish cycle and an increased
sensitivity to changes in glucose-6-phosphate and oxidized
glutathione while, for example, not being able to tolerate an
environment in which a large oxidative load would lead to a
decrease in the concentration of glucose-6-phosphate to less than
0.3 mM. Individuals with a Class II G6PD variant will have a
NADPH redox cycle that has an even slower response time as well
as an even greater sensitivity to changes in the concentrations of
NADPtotal, oxidized glutathione and glucose-6-phosphate. Fur-
thermore, these patients will not tolerate an environment in which
a large oxidative load would lead to a decrease in the
concentration of glucose-6-phosphate to less than 2 mM.
NADPH Redox Cycle Hypothesis
Individuals who have inherited a Class I variant of G6PD suffer
from chronic hemolytic anemia, whereas individuals who have
inherited a Class II variant develop significant hemolysis only
when oxidative stress is induced. An increase in oxidative stress
leads to a shift in the operating point toward higher values of r
and, concomitantly, to a possible transition into Systemic Region c.
These observations have prompted us to set forth the following
hypothesis:
When the NADPH redox cycle functions within Systemic Region c, the
individual will suffer from hemolytic anemia. Furthermore, individuals
with a Class II/III variant only transiently operate within Systemic
Region c because they require an extra source of oxidative stress to
Table 5. Statistical comparison of the local performance of
NADPH redox cycles that harbor G6PD variants that belong to
different classes.
Class Criterion1
Reference Comparison 1* 2367
I 16.56 2.56 0.96 6.58 3.56
652.80 68.66 63.39 65.08 60.18
II 4.77{ 0.62 0.18 5.54 3.54
66.42 61.05 60.24 64.66 60.19
III 1.22{ 0.04 0.01 0.76 3.50
±0.19 ±0.03 ±0.01 ±0.60 60.10
IV 1.09 0.01 0.01 0.32 3.50
±0.03 ±0.01 ±0.00 ±0.11 60.14
II 4.77 0.62 0.18 5.54 3.54
66.42 61.05 60.24 64.66 60.19
III 1.22 0.04 0.01 0.76 3.50
±0.19 ±0.03 ±0.01 ±0.60 60.10
IV 1.09 0.01 0.01 0.32 3.50
±0.03 ±0.01 ±0.00 ±0.11 60.14
III 1.22 0.04 0.01 0.76 3.50
60.19 60.03 60.01 60.60 60.10
IV 1.09 0.01 0.01 0.32 3.50
60.03 ±0.01 ±0.00 ±0.11 60.14
The class in the first column (Reference) has its mean local performance
compared to that of the classes in the second column (Comparison). To
improve local performance, one must have low values for the criteria.
1The criteria were listed under the sub-section ‘‘Criteria for Functional
Effectiveness’’ of the Methods Section.
*Parametric methods of analysis were used in all cases except for criterion 1, in
which case the analysis was conducted using non-parametric methods that are
based on the comparison of medians. In this case the medians are: 2.65, 2.39,
1.16 and 1.08 for Classes I through IV, respectively.
{Values italicized: p-value.0.05 (insignificant);
{Values bold: p-value,0.05 (significant).
doi:10.1371/journal.pone.0013031.t005
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PLoS ONE | www.plosone.org 9 September 2010 | Volume 5 | Issue 9 | e13031develop clinical manifestations. However, individuals with a Class I
variant always operate within Systemic Region c because their hemolytic
anemia is chronic.
To reconcile this hypothesis with our observations, we need to
understand why Class I variants aren’t mostly located within
Systemic Region c (Figure 3). One possibility may reside in the
stability of Class I variants of G6PD. Cheng et al [37] suggested that
a correlation exists between mutations in evolutionary conserved
amino acids and clinical manifestations. They showed the
following trend: ‘‘as the severity of clinical consequences reduces
from Class I, II and III, the percentage of mutations in the top
pentad (conservation score .0.8) decreases from 51% (21/41) for
class I to 41% (12/29) for class II and to 24% (5/21) for Class III.’’
Furthermore, the majority of Class I mutations are clustered near
the dimer interface and NADP binding site for structural stability,
or are deletion mutations [8]. In addition, of 40 Class I variants
described in [38], 32 had highly decreased thermostability while 4
had decreased thermostability and 4 were classified as normal.
Hence, one may speculate that Class I variants have a lower
stability. In turn, a lower stability may lead to a sharp decrease in
activity as erythrocytes age, eventually attaining a threshold
(within Systemic Region c) below which erythrocytes lyse. Chronic
non-spherocytic haemolytic anemia ensues from the hematopoi-
etic system being unable to compensate for the shortened
erythrocyte lifespan with sufficiently increased reticulocytosis. On
the other hand, because G6PD in these patients is sampled from a
younger cell population, the overall G6PD activities are similar to
those of Class II variants, which have longer erythrocyte lifespans.
A systematic reexamination of our modeling assumptions by
means of the design space analysis suggests other testable
possibilities for reconciling the observations with our hypothesis
Table 7. Statistical comparison of the biochemical properties of the G6PD from the various classes.
Class Kinetic Parameter (Medians)
Reference Comparison Number of variants G6PD activity (%) KM,G6P (mM) KM,NADPz (mM) KI,NADPH (mM)*
I 25 4.4 40.0 6.0 7.6
II 12 3.3{ 42.2 5.4 30.5
III 21 27.0{ 39.0 5.2 18.0
IV 9 77.5 48.0 6.3 24.0
II 12 3.3 42.2 5.4 30.5
III 21 27.0 39.0 5.2 18.0
IV 9 77.5 48.0 6.3 24.0
III 21 27.0 39.0 5.2 18.0
IV 9 77.5 48.0 6.3 24.0
The class in the first column (Reference) has its median kinetic properties compared to those of the classes in the second column (Comparison).
*Non-parametric methods of analysis were used in all cases except for the analysis of KI,NADPH, in which case parametric methods of analysis were available. For KI,NADPH
the means are: 26.3, 60.9, 26.7 and 54.7 for Classes I through IV, respectively.
{Values italicized: p-value.0.05 (insignificant);
{Values bold: p-value,0.05 (significant).
doi:10.1371/journal.pone.0013031.t007
Figure 4. Location of operating points for Class I G6PD variants
with an hypothetical increase in KE,NADP+. Class I variants of G6PD
are subject to a different equilibrium between G6PD and NADP
+ which
results in increasing the value of KE,NADPz to 790 mM. Under this
circumstance, because ku, the y-axis, is directly proportional to
KE,NADPz, the operating points for Class I G6PD variants are located
in Systemic Region c. All other features of the design space are
described in the legends of Figures 2 and 3.
doi:10.1371/journal.pone.0013031.g004
Table 8. Kinetic properties of the P. falciparum G6PD and the
host G6PD [35].
Kinetic Parameter Host G6PD P. falciparum G6PD
VMax,G6PD (mMs
21)* 0.2 4.8
KM,G6P (mM) 27 11
KM,NADPz (mM) 1.4 0.8
KI,NADPH (mM) 16{ -
*The maximum velocity for synthesizing NADPH is twice the maximum velocity
of G6PD (to take into account the GO6PD activity). For further details see [4];
{- from [9].
doi:10.1371/journal.pone.0013031.t008
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I mutants exhibit a higher dissociation constant of the G6PD-
NADP
+ complex (Figure 4).
Suggested Design Principle
Overall these results illustrate the importance of maintaining
both good local performance and large global tolerance and
suggest the following design principle: kuw1, rv 1{kc
ku and kcv1.
In order for Systemic Regime a to exist, kc should be less than 1.
In biological terms, this can be achieved by selecting for a GSR
whose apparent Michaelis constant for NADPH is lower than the
total concentration of NADP. To avoid Systemic Regime b, which
characterizes the worst local performance, ku should be larger
than 1. In this case, G6PD should display an apparent Michaelis
constant for NADP
+ than is higher than the total concentration of
NADP. To achieve the best Systemic Region (a) r should be less
than the ratio (1{kc)=ku. In biological terms, the apparent
maximal velocity of GSR should be much lower than that for
G6PD.
Infection by Plasmodium falciparum
As one final point, it seems that natural selection has produced
a parasite, P. falciparum, that is capable of adapting to G6PD-
deficient erythrocytes by converting a deficient NADPH redox
cycle into one that has both robust local behavior and large global
tolerance. In the particular study that we have analyzed [35], the
host inherited a G6PD variant that leads to an operating point in
Systemic Regime c. In order to adapt to this hostile environment,
P. falciparum has to synthesize its own G6PD and is burdened with
the associated energetic costs; the host cells, however, cannot
Table 9. Evaluation of Local Performance and Global Tolerance for the NADPH redox cycle in human erythrocytes infected with P.
falciparum.
Local Performance
Criterion1 Preference| Quantitative value{ Optimum value{
1 Y 1.26 1
2 Y 0.04 0
3 Y 0.02 0
4 X 1.00 1
5 Y 0.00 0
6 Y 0.92 0
7 Y 3.64 2
Global Tolerance
Variable or Parameter Tolerance Value* Variable or Parameter Tolerance value
KI,NADPH [42610
3 KM,NADPH 122]
G6P [46 VMax,G6PD [25
KM,G6P 46] VMax,GSR 25]
KE,NADPz 46] KM,GSSG [22
2,3{DPG 94] GSSG 22]
KI,2,3{DPG [94 NADPtotal [21
KM,NADPz 54]
1The criteria were listed under the sub-section ‘‘Criteria for Functional Effectiveness’’ of the Methods Section;
|To improve performance, one must have either a high (X) or a low (Y) value for the associated criterion;
{The quantitative value was determined by using the data from Tables 8 and 1 and the analytical expressions listed in Table S1, S2 of the Text S1;
{The optimum value was determined analytically except for criterion 7 which had to be determined numerically;
*[T represents tolerance to a fold decrease and T] represents tolerance to a fold increase.
doi:10.1371/journal.pone.0013031.t009
Figure 5. Location of uninfected (black diamond) and infected
erythrocytes (black square) in design space. The operating point
of the P. falciparum-infected erythrocyte is located in Systemic Region a
whereas the operating point of uninfected erythrocytes is located in
Systemic Region c. All other features are described in the legends of
Figures 2 and 3.
doi:10.1371/journal.pone.0013031.g005
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destruction by the P. falciparum.
Conclusion
Our analysis of the NADPH redox cycle in human erythrocytes
provides a clear example of how system design space concepts
serve as a framework to understand quantitative physiological and
pathological behavior. It allowed us to define and characterize
three different phenotypic regions: physiological (Systemic regime
a), pathological (Systemic regime c) and potentially lethal
(Systemic regime b). This example, and others [6,7,39], illustrates
the utility of creating a design space that illuminates the function,
design and fitness of the system. The system design space includes
relationships among genotype, phenotype and environment. It
provides an important framework to characterize the quantitative
behavior of a system, and to compare wild-type and mutant
variants. We know of no other approach that is able efficiently to
accomplish these desirable objectives.
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